| Identification | Back Directory | [Name]
Benzamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[2,3-dihydro-3-methyl-1-(1-methyl-4-piperidinyl)-2-oxo-1H-benzimidazol-5-yl]-3-[[4-(dimethylamino)cyclohexyl]ethylamino]-2-methyl- | [CAS]
3026848-13-2 | [Synonyms]
Benzamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[2,3-dihydro-3-methyl-1-(1-methyl-4-piperidinyl)-2-oxo-1H-benzimidazol-5-yl]-3-[[4-(dimethylamino)cyclohexyl]ethylamino]-2-methyl- | [Molecular Formula]
C40H55N7O3 | [MOL File]
3026848-13-2.mol | [Molecular Weight]
681.91 |
| Hazard Information | Back Directory | [Uses]
EZH2-IN-19 (conpound N40) is a potent inhibitor of enhancer of zeste homolog 2 (EZH2) WT, with the IC50 of 0.32 nM. EZH2-IN-19 plays an important role in cancer research[1]. | [IC 50]
EZH2 WT: 0.32 nM (IC50); EZH2 Y641F mutant type: 0.03 nM (IC50); EZH2 Y641N: 0.08 nM (IC50) | [References]
[1] Di Wu, et al. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas. Bioorg Med Chem. 2024 May 1:105:117725. DOI:10.1016/j.bmc.2024.117725 |
|
|